CAR-T therapy has transformed treatment options for hematologic malignancies, but broader access remains limited by complex, centralized manufacturing, extended vein-to-vein timelines, and high production costs.
This white paper presents the MARS Atlas® platform with the GoFast™ workflow as a closed, automated approach for rapid autologous CAR-T manufacturing. The GoFast solution streamlines processes for CAR-T production. In fact, the GoFast represents a significant innovation in the field. The workflow integrates T-cell selection, activation and transduction, and harvest into a streamlined process designed to produce CAR-T cells in under 72 hours.
GoFast ensures high consistency and reproducibility. Validation studies using fresh and frozen leukopak, frozen PBMC, and multiple myeloma patient samples demonstrated consistent CAR+ T-cell production, strong T-cell activation, and functional anti-tumor activity in in vitro and in vivo models. The paper also outlines a cost-of-goods breakdown below $9,500 per patient, highlighting the potential of rapid, automated manufacturing to support more accessible CAR-T workflows. Overall, implementing GoFast can help accelerate therapy development advancement.
